IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 191 filers reported holding IMMUNOVANT INC in Q3 2023. The put-call ratio across all filers is 2.28 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,700 | +113.8% | 3,118 | +5.7% | 0.01% | +100.0% |
| Q2 2023 | $55,980 | +52.5% | 2,951 | +24.7% | 0.00% | +50.0% |
| Q1 2023 | $36,697 | -24.9% | 2,366 | -14.1% | 0.00% | 0.0% |
| Q4 2022 | $48,884 | +256.8% | 2,754 | +12.2% | 0.00% | +100.0% |
| Q3 2022 | $13,699 | -9.9% | 2,455 | -11.0% | 0.00% | 0.0% |
| Q1 2022 | $15,197 | -55.4% | 2,758 | -31.0% | 0.00% | – |
| Q4 2021 | $34,046 | -27.5% | 3,996 | -26.1% | 0.00% | -100.0% |
| Q3 2021 | $46,969 | -63.7% | 5,405 | -55.9% | 0.00% | -50.0% |
| Q2 2021 | $129,430 | -13.8% | 12,245 | +30.8% | 0.00% | 0.0% |
| Q1 2021 | $150,134 | -68.5% | 9,360 | -9.2% | 0.00% | -71.4% |
| Q4 2020 | $475,896 | +31.3% | 10,303 | 0.0% | 0.01% | +16.7% |
| Q3 2020 | $362,563 | +128.2% | 10,303 | +57.9% | 0.01% | +100.0% |
| Q2 2020 | $158,859 | – | 6,524 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |